Spec. MD. Elkhan Mammadov
Medical Specialist
Areas Of Interests
Cancer diagnosis and treatment
Cytotoxic chemotherapy
Hormone therapy
Targeted therapy (smart drug therapy)
Immunotherapy
Education:
- 2004-2010 Azerbaijan Medical University
- 2014-2019, Istanbul University, Istanbul Faculty of Medicine, Internal Medicine Specialist
- 2019-2022 Istanbul Medipol Mega University Hospital, Oncology Subspecialty
- 5 years as an Internal Medicine Specialist
- 3 years of subspecialty training in oncology
Specialization Thesis:
- Evaluation of Clinical and Laboratory Findings and Treatment Outcomes in Patients Diagnosed with Essential Thrombocythemia
- A randomized, double-blind, phase 3 study of platinum-based chemotherapy with or without INCMGA00012 in first-line metastatic squamous and non-squamous non-small cell lung cancer
- A Phase III, Double-Blind, Placebo-Controlled Randomized Trial Evaluating the Combination of Ipatasertib, Atezolizumab, and Paclitaxel in Patients with Locally Advanced, Unresectable, or Metastatic Triple-Negative Breast Cancer (C041101 IPATUNITY 170 MINISTRY CODE: 19-ROC-05)
- "Phase 3 Randomized Study Comparing Amivantamab and Lazertinib Combination Therapy with Osimertinib and Lazertinib Monotherapy as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer" titled and 73841937NSC3003 (Ministry code: 202003090)
- 61186372NSC3001 (Ministry code: 202003118) titled "Randomized, Open-Label Phase 3 Study Comparing Amivantamab and Carboplatin Pemetrexed Combination Therapy with Carboplatin Pemetrexed Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20ins Mutation." Open-Label Phase 3 Study."
- ER (+), HER2 (-) advanced breast cancer - AMEERA-5, EFC15935: A randomized, multicenter, double-blind Phase 3 study comparing letrozole plus palbociclib with SAR439859 plus palbociclib in patients who have not received systemic anti-cancer therapy for EFC15935 (Ministry code: 202003120)"
- Phase III, Open-Label Study Comparing Atezolizumab and Tiragolumab with Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Platinum-Based Chemoradiation Therapy Unresectable Stage III Non-Small Cell Lung Cancer Patients: An Open-Label, Randomized Study Comparing Atezolizumab and Tiragolumab with Durvalumab (Skyscraper-03), GO41854, SKY03
- A Phase III, randomized, double-blind, placebo-controlled study evaluating atezolizumab plus carboplatin and etoposide with or without tiragolumab (anti-Tigit antibody) in untreated extensive-stage small cell lung cancer patients, go41767 skyscraper02
- Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy with or without Olaparib (MK7339) in Newly Diagnosed, Untreated, Limited-Stage Small Cell Lung Cancer (SE-SCLC) Compared to Concurrent Chemoradiotherapy Alone in Patients, Randomized, Double-Blind, Placebo-Controlled, Pembrolizumab and "MK7339-013 Phase 3 Study" (Ministry code: 202003108)
- Estrogen Receptor Positive, Her2 Negative, A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gdc9545 and Palbociclib Combination Compared to Letrozole and Palbociclib Combination in Locally Advanced or Metastatic Breast Cancer, BO41843, PersevERA
- Completely Resected Stage II-III Non-Small Cell Lung Cancer (MeRmaiD-1) A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-Based Chemotherapy” and “D910LC00001(Mermaid)-1) (Ministry code: 202003050)
- A Phase 3, Randomized, Double-Blind Study Comparing Pembrolizumab with or without Adjuvant Chemotherapy versus Placebo in the Postoperative Treatment of Newly Diagnosed High-Risk Endometrial Cancer (KEYNOTE-B21 / ENGOT-en11 / GOG) -3053)" and "MK3475-B21 (Ministry code: 202003126)
- PIK3CA Registration Study: A Descriptive Study of PIK3CA Mutations in HR+/Her2- Advanced Breast Cancer Patients” and “CBYL719C2401 (Ministry code: -)
- "A Randomized, Controlled, Multicenter Study of Neoadjuvant Osimertinib Monotherapy or in Combination with Chemotherapy in Patients with Epidermal Growth Factor Receptor Mutation-Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA) A Randomized, Controlled, Multicenter, Three-Arm Phase III Study Comparing Neoadjuvant Osimertinib Alone Versus Standard Chemotherapy in Combination with Neoadjuvant Chemotherapy" and "D516AC00001 (NeoADAURA) (Ministry code: 202003046)
- In Patients with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) and "MK7339 -012" Compared to Durvalumab After Concurrent Chemoradiotherapy, Pembrolizumab (MK-3475) with or without Olaparib Phase 3 Study" and "MK7339-012" (Ministry code: 2020030119)
- In Patients with Previously Untreated Advanced-Stage Small Cell Lung Cancer (MSLCL) Patients: A Randomized, Double-Blind, Multicenter, Phase III Study to Compare the Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) Centralized, Phase III Study {HLX10-005-SCLC301 (Ministry code: 19-PRX-26)}
- Chemotherapy (carboplatin-nanoparticle albumin-bound (nab)-paclitaxel) versus chemotherapy (carboplatin-nab-paclitaxel) + HLX10 (recombinant anti-PD-1) as first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
• Turkish Medical Oncology Association•
ESMO: European Society for Medical
Oncology• ASCO: American Society of Clinical Oncology
ESMO: European Society for Medical
Oncology• ASCO: American Society of Clinical Oncology
